Here are the DEF 14A proxy statements from Zymeworks Inc. (ZYME) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ZYME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZYME filings page.
Zymeworks Inc. (ZYME) asks stockholders to vote at its virtual annual meeting on December 15, 2026, on six proposals: elect director nominees Brian N. Cherry, Gregory A. Ciongoli and Oleg Nodelman; approve named executive officer compensation on an advisory basis; set the frequency of future compensation votes; approve the 2026 Employee Stock Purchase Plan; amend the charter to declassify the board; and ratify the auditor appointment. The board recommends voting FOR the nominees and Proposals 2, 4, 5 and 6, and 1 YEAR for Proposal 3.
If approved, Proposal 5 would begin annual one-year elections for directors whose terms expire starting at the 2027 annual meeting, with the staggered-board structure phased out by the 2029 annual meeting; directors elected at the 2026 meeting would still serve three-year terms. On the October 21, 2026 record date, 70,475,386 common shares were held by registered stockholders, and 1,424,533 exchangeable shares were eligible to vote. The prior annual meeting’s advisory compensation vote received approximately 94% support among votes cast, excluding broker non-votes and abstentions.